@article{MTMT:34272036,
	title = {Outcomes of Exeter cemented total hip arthroplasty in a county hospital. survivorship of eight hundred and ninety four hips with a minimum ten-year follow up.},
	url = {https://m2.mtmt.hu/api/publication/34272036},
	author = {Kristóf, Jánvári and Gupta, Devanshu and Szabó, László and Bucsi, László and Zahár, Ákos},
	doi = {10.1007/s00264-023-06026-y},
	journal-iso = {INT ORTHOP},
	journal = {INTERNATIONAL ORTHOPAEDICS},
	volume = {48},
	unique-id = {34272036},
	issn = {0341-2695},
	abstract = {A total of 894 hips were evaluated to describe the survivorship of Exeter cemented femoral stems and report the outcomes and complications of our 'Exeter- era', and there is no study from Central or Eastern Europe demonstrating similar results.Between January 2000 and December 2009, a total of 894 hips were included who underwent Exeter universal and V40 femoral stems with a mean follow up of 13 years. Cemented Exeter low profile polyethylene cups were used in 889 patients (99.4%) cups. Harris hip score (HHS) was used and statistical outcome measures were calculated with revision as an endpoint for aseptic loosening of the stem, aseptic loosening of any component, all-cause revision of the stem, and all-cause revision of the hip.A total of 103 patients died and 129 (14.4%) operated hips were lost to follow-up before ten years. Out of the 662, ten stems (1.5%) were revised for aseptic loosening. Aseptic loosening of any component was the reason for revision in 43 cases (6.5%), consisting of 40 cup revisions and ten stem exchanges. Periprosthetic fracture occurred in 17 cases (1.9%) Periprosthetic joint infection occurred in 18 cases (2.01%). Three cups were exchanged for recurrent dislocation, and two stems had broken.Exeter hip system has provided reproducible results across different centres worldwide, as it did in our series. Thorough surgical and cementing technique is of utmost importance for achieving these results. The cup is the weak point of the system and use of a hybrid system is worth considering.},
	keywords = {Cemented THA; Exeter; V40 femoral stem},
	year = {2024},
	eissn = {1432-5195},
	pages = {729-735}
}

@article{MTMT:34486941,
	title = {Nagy intenzitású rosuvastatin vagy rosuvastatin/ezetimib kombinációs lipidcsökkentő terápia hatékonysága hypercholesterinaemiás, igen nagy kardiovaszkuláris rizikójú magyar betegekben – a 3T-FIGHT-vizsgálat első eredményei = Efficacy of high-intensity rosuvastatin or rosuvastatin/ezetimibe combined lipid-lowering therapy in Hungarian patients with hypercholesterolemia at very-high cardiovascular risk – the first results of the 3T-FIGHT study},
	url = {https://m2.mtmt.hu/api/publication/34486941},
	author = {Reiber, István and Márk, László and Együd, Ferenc Mihály and Mező, Izabella and Császár, Albert},
	doi = {10.26430/CHUNGARICA.2023.53.6.633},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34486941},
	issn = {0133-5596},
	year = {2023},
	eissn = {1588-0230},
	pages = {633-639}
}

@article{MTMT:34442068,
	title = {Az elsődleges fejfájások és gyógyszeres kezelésük. Tenziós fejfájás és migrén},
	url = {https://m2.mtmt.hu/api/publication/34442068},
	author = {Kerényi, Levente},
	journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	volume = {28},
	unique-id = {34442068},
	issn = {1219-8641},
	year = {2023},
	pages = {415-418}
}

@article{MTMT:34205953,
	title = {A fájdalomcsillapítás, az arthrosis és a derékfájás ellátásának újdonságai},
	url = {https://m2.mtmt.hu/api/publication/34205953},
	author = {Pulai, Judit},
	journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	volume = {28},
	unique-id = {34205953},
	issn = {1219-8641},
	year = {2023},
	pages = {340-344}
}

@article{MTMT:34092156,
	title = {Híd a szakadék felett : A lipidcsökkentő kezelés ajánlásai és a valósága},
	url = {https://m2.mtmt.hu/api/publication/34092156},
	author = {Reiber, István and Mező, Izabella},
	doi = {10.33616/lam.33.0364},
	journal-iso = {LEGE ART MED},
	journal = {LEGE ARTIS MEDICINAE},
	volume = {33},
	unique-id = {34092156},
	issn = {0866-4811},
	abstract = {2023-ban evidenciaként kell elfogadunk azt a tényt, hogy az emelkedett LDL-C okozó rizikótényezője az atheroscleroticus érbetegségeknek és a következményként fellépő érkatasztrófáknak (myocardialis infarktus, stroke, perifériás érelzáródás). Intenzív lipidterápiával, azaz intenzív dózisú statin (20–40 mg rosuvastatin vagy 40–80 mg atorvastatin) és ezetimib kombinációjának alkalmazásával 50% feletti mértékben csökkenthető az LDL-C-szint, és így a kezeltek nagy részénél elérhetőek lennének a hazai és a nemzetközi ajánlásokban szereplő LDL-C-célértékek. Ugyan - akkor jól ismertek azok az adatok, hogy a dyslipidaemiás betegeknél nagyon rossz a lipidcsökkentő gyógyszerek vonatkozásában a terápiás fegyelem (gyenge adherencia, perzisztencia). A dyslipidaemiás betegek terápiás együttműködésének javításához a kezelőorvosnak határozott meggyőződéssel kell képviselni, hogy az LDL-C hatásos csökkentésével megelőzhetőek az érkatasztrófák és azok ismétlődése. A rendelkezésre álló gyógyszerek biztonságosak, hatásosak. A betegeket individuálisan megválasztott kommunikációval meg kell győzni, hogy az emelkedett LDL-C-szint idő előtti érkárosodáshoz vezet, és az LDL-C hatásos csökkentésével a már kialakult ér - elváltozások visszafordíthatóak, javíthatók. A betegek rendszeres ellenőrzésével a szükséges terápiás együttműködést hosszú távon fenn kell tartani.},
	year = {2023},
	eissn = {2063-4161},
	pages = {364-369}
}

@article{MTMT:34072590,
	title = {Invalidity of Tokyo guidelines in acute biliary pancreatitis : A multicenter cohort analysis of 944 pancreatitis cases},
	url = {https://m2.mtmt.hu/api/publication/34072590},
	author = {Juhász, Márk Félix and Tóháti, Rebeka and Jászai, Viktória Adrienn and Molnár, Regina and Borbásné Farkas, Kornélia and Czakó, László and Vincze, Áron and Erőss, Bálint Mihály and Szentesi, Andrea Ildikó and Izbéki, Ferenc and Papp, Mária and Hegyi, Péter and Párniczky, Andrea},
	doi = {10.1002/ueg2.12402},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {34072590},
	issn = {2050-6406},
	abstract = {There is a noteworthy overlap between the clinical picture of biliary acute pancreatitis (AP) and the 2018 Tokyo guidelines currently used for the diagnosis of cholangitis (AC) and cholecystitis (CC). This can lead to significant antibiotic and endoscopic retrograde cholangiopancreatography (ERCP) overuse.We aimed to assess the on-admission prevalence of AC/CC according to the 2018 Tokyo guidelines (TG18) in a cohort of biliary AP patients, and its association with antibiotic use, ERCP and clinically relevant endpoints.We conducted a secondary analysis of the Hungarian Pancreatic Study Group's prospective multicenter registry of 2195 AP cases. We grouped and compared biliary cases (n = 944) based on the on-admission fulfillment of definite AC/CC according to TG18. Aside from antibiotic use, we evaluated mortality, AC/CC/AP severity, ERCP performance and length of hospitalization. We also conducted a literature review discussing each criteria of the TG18 in the context of AP.27.8% of biliary AP cases fulfilled TG18 for both AC and CC, 22.5% for CC only and 20.8% for AC only. Antibiotic use was high (77.4%). About 2/3 of the AC/CC cases were mild, around 10% severe. Mortality was below 1% in mild and moderate AC/CC patients, but considerably higher in severe cases (12.8% and 21.2% in AC and CC). ERCP was performed in 89.3% of AC cases, common bile duct stones were found in 41.1%.Around 70% of biliary AP patients fulfilled the TG18 for AC/CC, associated with a high rate of antibiotic use. Mortality in presumed mild or moderate AC/CC is low. Each of the laboratory and clinical criteria are commonly fulfilled in biliary AP, single imaging findings are also unspecific-AP specific diagnostic criteria are needed, as the prevalence of AC/CC are likely greatly overestimated. Randomized trials testing antibiotic use are also warranted.},
	keywords = {MORTALITY; Antibiotic use; cholangitis; endoscopic retrograde cholangiopancreatography; cholecystitis; ERCP; STONES; Biliary acute pancreatitis; 2018 Tokyo guidelines},
	year = {2023},
	eissn = {2050-6414},
	pages = {767-774},
	orcid-numbers = {Molnár, Regina/0009-0009-7067-1647; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Czakó, László/0000-0002-6331-0802; Vincze, Áron/0000-0003-2217-7686; Erőss, Bálint Mihály/0000-0003-3658-8427; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Izbéki, Ferenc/0000-0001-7767-4319; Papp, Mária/0000-0003-3662-4010; Hegyi, Péter/0000-0003-0399-7259; Váncsa, Szilárd/0000-0002-9347-8163; Márta, Katalin/0000-0002-2213-4865; Nagy, Rita/0000-0002-2663-4912; Imrei, Marcell/0000-0003-0175-7462; Maurovich-Horvat, Pál/0000-0003-0885-736X; Doros, Attila/0000-0002-6496-9895; Zubek, László/0000-0003-0583-3290; Gál, János/0000-0001-9160-6478}
}

@article{MTMT:33864451,
	title = {Detailed characteristics of post-discharge mortality in acute pancreatitis},
	url = {https://m2.mtmt.hu/api/publication/33864451},
	author = {Turcsiné Czapári, Dóra and Váradi, Alex and Borbásné Farkas, Kornélia and Nyári, Gergely Róbert and Márta, Katalin and Váncsa, Szilárd and Nagy, Rita and Teutsch, Brigitta and Bunduc, Stefania and Erőss, Bálint Mihály and Czakó, László and Vincze, Áron and Izbéki, Ferenc and Papp, Mária and Merkely, Béla Péter and Szentesi, Andrea Ildikó and Hegyi, Péter},
	doi = {10.1053/j.gastro.2023.05.028},
	journal-iso = {GASTROENTEROLOGY},
	journal = {GASTROENTEROLOGY},
	volume = {165},
	unique-id = {33864451},
	issn = {0016-5085},
	abstract = {The in-hospital survival of patients suffering from acute pancreatitis (AP) is 95-98%. However, there is growing evidence that patients discharged after AP may be at risk of serious morbidity and mortality. Here, we aimed to investigate the risk, causes, and predictors of the most severe consequence of the post-AP period: mortality.2,613, well-characterized patients from twenty-five centers were collected and followed by the Hungarian Pancreatic Study Group between 2012 and 2021. A general and a hospital-based population was used as the control group.After an AP episode patients have an approximately three-fold higher incidence rate of mortality than the general population (0.0404vs.0.0130 person-years). First-year mortality after discharge was almost double than in-hospital mortality (5.5%vs.3.5%), with 3.0% occurring in the first 90-day period. Age, comorbidities, and severity were the most significant independent risk factors for death following AP. Furthermore, multivariate analysis identified creatinine, glucose, and pleural fluid on admission as independent risk factors associated with post-discharge mortality. In the first 90-day period, cardiac failure and AP-related sepsis were among the main causes of death following discharge, while cancer-related cachexia and non-AP-related infection were the key causes in the later phase.Almost as many patients in our cohort die in the first 90-day period after discharge as during their hospital stay. Evaluation of cardiovascular status, follow-up of local complications, and cachexia-preventing oncological care should be an essential part of post-AP patient care. Future study protocols in AP must include at least a 90-day follow-up period after discharge.},
	year = {2023},
	eissn = {1528-0012},
	pages = {682-695},
	orcid-numbers = {Váradi, Alex/0000-0001-8229-6340; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Márta, Katalin/0000-0002-2213-4865; Váncsa, Szilárd/0000-0002-9347-8163; Nagy, Rita/0000-0002-2663-4912; Teutsch, Brigitta/0000-0002-9530-7886; Erőss, Bálint Mihály/0000-0003-3658-8427; Czakó, László/0000-0002-6331-0802; Vincze, Áron/0000-0003-2217-7686; Izbéki, Ferenc/0000-0001-7767-4319; Papp, Mária/0000-0003-3662-4010; Merkely, Béla Péter/0000-0001-6514-0723; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259; Imrei, Marcell/0000-0003-0175-7462; Németh, Balázs/0000-0001-5338-7577; Tiszlavicz, László/0000-0003-1134-6587; Oláh, Orsolya/0000-0002-5731-4030; Vitális, Zsuzsanna/0000-0001-8198-5312; Doros, Attila/0000-0002-6496-9895}
}

@article{MTMT:33761635,
	title = {Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course : Post hoc analysis of a prospectively collected international registry},
	url = {https://m2.mtmt.hu/api/publication/33761635},
	author = {Váncsa, Szilárd and Sipos, Zoltán and Váradi, Alex and Nagy, Rita and Ocskay, Klementina and Juhász, Márk Félix and Márta, Katalin and Teutsch, Brigitta and Mikó, Alexandra and Hegyi, Péter Jenő and Vincze, Áron and Izbéki, Ferenc and Czakó, László and Papp, Mária and Hamvas, József and Varga, Márta and Török, Imola and Mickevicius, Artautas and Erőss, Bálint Mihály and Párniczky, Andrea and Szentesi, Andrea Ildikó and Pár, Gabriella and Hegyi, Péter},
	doi = {10.1002/ueg2.12389},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {33761635},
	issn = {2050-6406},
	abstract = {Non-alcoholic fatty liver disease (NAFLD) is a proven risk factor for acute pancreatitis (AP). However, NAFLD has recently been redefined as metabolic-associated fatty liver disease (MAFLD). In this post hoc analysis, we quantified the effect of MAFLD on the outcomes of AP.We identified our patients from the multicentric, prospective International Acute Pancreatitis Registry of the Hungarian Pancreatic Study Group. Next, we compared AP patients with and without MAFLD and the individual components of MAFLD regarding in-hospital mortality and AP severity based on the revised Atlanta classification. Lastly, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression analysis.MAFLD had a high prevalence in AP, 39% (801/2053). MAFLD increased the odds of moderate-to-severe AP (OR = 1.43, CI: 1.09-1.89). However, the odds of in-hospital mortality (OR = 0.89, CI: 0.42-1.89) and severe AP (OR = 1.70, CI: 0.97-3.01) were not higher in the MAFLD group. Out of the three diagnostic criteria of MAFLD, the highest odds of severe AP was in the group based on metabolic risk abnormalities (OR = 2.68, CI: 1.39-5.09). In addition, the presence of one, two, and three diagnostic criteria dose-dependently increased the odds of moderate-to-severe AP (OR = 1.23, CI: 0.88-1.70, OR = 1.38, CI: 0.93-2.04, and OR = 3.04, CI: 1.63-5.70, respectively) and severe AP (OR = 1.13, CI: 0.54-2.27, OR = 2.08, CI: 0.97-4.35, and OR = 4.76, CI: 1.50-15.4, respectively). Furthermore, in patients with alcohol abuse and aged ≥60 years, the effect of MAFLD became insignificant.MAFLD is associated with AP severity, which varies based on the components of its diagnostic criteria. Furthermore, MAFLD shows a dose-dependent effect on the outcomes of AP.},
	keywords = {MORTALITY; Prognosis; metabolic syndrome; SEVERITY; Acute pancreatitis; STEATOSIS; Non-Alcoholic Fatty Liver Disease; NAFLD; MAFLD; Metabolic-associated fatty liver disease},
	year = {2023},
	eissn = {2050-6414},
	pages = {371-382},
	orcid-numbers = {Váncsa, Szilárd/0000-0002-9347-8163; Sipos, Zoltán/0000-0001-7845-8116; Váradi, Alex/0000-0001-8229-6340; Nagy, Rita/0000-0002-2663-4912; Ocskay, Klementina/0000-0001-5848-2506; Márta, Katalin/0000-0002-2213-4865; Teutsch, Brigitta/0000-0002-9530-7886; Vincze, Áron/0000-0003-2217-7686; Izbéki, Ferenc/0000-0001-7767-4319; Czakó, László/0000-0002-6331-0802; Papp, Mária/0000-0003-3662-4010; Erőss, Bálint Mihály/0000-0003-3658-8427; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259; Imrei, Marcell/0000-0003-0175-7462; Németh, Balázs/0000-0001-5338-7577; Maurovich-Horvat, Pál/0000-0003-0885-736X; Doros, Attila/0000-0002-6496-9895; Zubek, László/0000-0003-0583-3290; Gál, János/0000-0001-9160-6478; Tari, Edina/0000-0002-8540-0614}
}

@article{MTMT:33208671,
	title = {Point-of-care ultrasound improves clinical outcomes in patients with acute onset dyspnea: a systematic review and meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/33208671},
	author = {Szabó, Gergő Vilmos and Szigetváry, Csenge and Szabó, László and Dembrovszky, Fanni and Rottler, Máté and Ocskay, Klementina and Madzsar, Stefanie and Hegyi, Péter and Molnár, Zsolt},
	doi = {10.1007/s11739-022-03126-2},
	journal-iso = {INTERN EMERG MED},
	journal = {INTERNAL AND EMERGENCY MEDICINE},
	volume = {18},
	unique-id = {33208671},
	issn = {1828-0447},
	abstract = {The early, appropriate management of acute onset dyspnea is important but often challenging. The aim of this study was to investigate the effects of the use of Point-of-Care Ultrasound (PoCUS) versus conventional management on clinical outcomes in patients with acute onset dyspnea. The Cochrane Library, MEDLINE, EMBASE and reference lists were searched to identify eligible trials (inception to October 14, 2021). There were no language restrictions. Randomized controlled trials (RCTs), and prospective and retrospective cohort studies that compared PoCUS with conventional diagnostic modalities (controls) in patients with acute onset dyspnea were included. Two independent reviewers extracted data and assessed the risk of bias. Disagreements were resolved by consensus. The primary study outcomes were time to diagnosis, time to treatment, and length of stay (LOS). Secondary outcomes included rate of appropriate treatment, 30-day re-admission rate, and mortality. We included eight RCTs and six observational studies with a total of 5393 participants. Heterogeneity across studies was variable (from low to considerable), with overall low or moderate study quality and low or moderate risk of bias (except one article with serious risk of bias). Time to diagnosis (mean difference [MD], - 63 min; 95% CI, - 115 to - 11 min] and time to treatment (MD, - 27 min; 95% CI - 43 to - 11 min) were significantly shorter in the PoCUS group. In-hospital LOS showed no differences between the two groups, but LOS in the Intensive Care Unit (MD, - 1.27 days; - 1.94 to - 0.61 days) was significantly shorter in the PoCUS group. Patients in the PoCUS group showed significantly higher odds of receiving appropriate therapy compared to controls (odds ratio [OR], 2.31; 95% CI, 1.61-3.32), but there was no significant effect on 30-day re-admission rate and in-hospital or 30-day mortality. Our results indicate that PoCUS use contributes to early diagnosis and better outcomes compared to conventional methods in patients admitted with acute onset dyspnea.},
	keywords = {clinical outcomes; Point-of-care ultrasound; Acute-onset dyspnea},
	year = {2023},
	eissn = {1970-9366},
	pages = {639-653},
	orcid-numbers = {Dembrovszky, Fanni/0000-0001-6953-3591; Rottler, Máté/0000-0003-0743-5595; Ocskay, Klementina/0000-0001-5848-2506; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34443426,
	title = {Új lehetőség az LDL-koleszterin csökkentésében: a bempedonsav},
	url = {https://m2.mtmt.hu/api/publication/34443426},
	author = {Reiber, István and Mező, Izabella and Noori, Ebrahim},
	journal-iso = {METABOLIZMUS},
	journal = {METABOLIZMUS},
	volume = {20},
	unique-id = {34443426},
	issn = {1589-7311},
	abstract = {A kardiovaszkuláris betegségek kialakulásának és a háttérben álló aterogén folyamat előrehaladásának az egyik legfontosabb kockázati tényezője a dyslipidaemia, azon belül is az emelkedett LDL-C-szint. A sztatinok kulcsszerepet játszanak a szív- és érrendszeri betegségek megelőzésében és csökkentésében. Sok beteg önmagában sztatinnal nem éri el az optimális LDL-C-szintet; mások nem tolerálják a sztatinterápiát. A további nem sztatin kezelési lehetőségek, köztük az ezetimib, a proprotein-konvertáz szubtilizin/kexin 9-es típusú enzimet gátlók gyakran szükségesek az ateroszklerotikus kardiovaszkuláris betegségek kockázatának további csökkentése érdekében. A bempedonsav egy új, nem sztatin gyógyszer, amely ugyanúgy gátolja a koleszterin-bioszintézist, mint a sztatinok. Prodrugként adjuk be, és csak a májban alakul át aktív hatóanyaggá, nem pedig az izmokban. A II. és III. fázisú klinikai vizsgálatok ígéretes eredményeket mutattak a biztonságosság és hatásosság tekintetében, akár monoterápiaként, akár sztatinokkal és/vagy ezetimibbel kombinálva, különböző betegprofilokban, beleértve a sztatinintoleranciában szenvedő betegeket is. Összefoglaljuk a bempedonsavról rendelkezésre álló eddigi ismereteket. Kulcsszavak: LDL-koleszterin, sztatinok, ezetimib, bempedonsav, kardiovaszkuláris rizikó},
	keywords = {SZÍV-ÉRRENDSZER BETEGSÉGEI; STATINOK; gyógyszeres terápia; LIPOPROTEINEK, LDL KOLESZTERIN; KOLESZTERINSZINT-CSÖKKENTŐ SZEREK},
	year = {2022},
	pages = {19-22}
}